ABSTRACT
Purpose Measuring visual acuity (VA) can be challenging in adults with cognitive impairment and young children. We developed an automatic system for measuring VA using Optokinetic Nystagmus (OKN).
Methods VA-OKN and VA by ETDRS (VA-ETDRS) were measured monocularly in healthy participants (n=23, age 30±12). VA was classified as reduced (n=22, >0.2 logMAR) or not (n=24, ≤0.2 logMAR) in each eye. VA-OKN stimulus was an array of drifting (5 deg/sec) vanishing disks presented in descending/ascending size order (0.0 to 1.0 logMAR in 0.1 logMAR steps). The stimulus was stepped every 2 seconds, and 10 sweeps were shown per eye. Eye tracking data determined when OKN activity ceased (descending sweep) or began (ascending sweep) to give an automated sweep VA. Sweep traces were randomized and assessed by a reviewer blinded to VA-ETDRS. A final per sweep VA and VA-OKN was thereby determined.
Results A single randomly selected eye was used for analysis. VA deficit group: There was no significant difference between overall mean VA-OKN and VA-ETDRS (p>0.05, paired t-test) and the r2 statistic was 0.84. The 95% limits of agreement were 0.19 logMAR. No VA deficit group: There was a 0.24 logMAR bias between VA-OKN and VA-ETDRS and no correlation was found (r2 = 0.06). However, the overall sensitivity/specificity for classification was 100%.
Conclusions A robust correlation between VA-ETDRS and VA-OKN was found. The method correctly detected a VA deficit.
Translational relevance OKN is a promising method for measuring VA in cognitively impaired adults and pre-verbal children.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by the Health Research Council of New Zealand (HRC 21/514). BT is supported by InnoHK and the Hong Kong Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the University of Auckland Human Participants Ethics Committee. The ethics approval reference is UAHPEC20318
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Financial support: Health Research Council of New Zealand (HRC 21/514). BT is supported by InnoHK and the Hong Kong Government.
Financial disclosures: The co-authors Turuwhenua and Thompson are co-inventors of the stimulus used in this work (Patent No. 11207023).
Data Availability
All data produced in the present work are contained in the manuscript
